Augmentation therapy, which involves the intravenous infusion of purified A1AT protein derived from human plasma, is a treatment approach used to supplement the deficient or dysfunctional A1AT in individuals with A1ATD. Here, SERPINA1 is linked to alpha 1-antitrypsin deficiency.